Entasis Therapeutics to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference
December 05 2018 - 8:00AM
Entasis Therapeutics (NASDAQ: ETTX), a clinical-stage
biopharmaceutical company focused on the discovery and development
of novel antibacterial products, announced that Manos Perros,
President and Chief Executive Officer, will present at the BMO
Capital Markets 2018 Prescriptions for Success Healthcare
Conference in New York, NY.
Event: BMO Capital Markets 2018 Prescriptions for
Success Healthcare ConferenceDate: December 12, 2018 at 2:00 PM
ETLocation: Mandarin Oriental Hotel, New York, NY
A live webcast of the presentation can be accessed
under "Investors & Media" in the “News & Events” section of
the Company's website at www.entasistx.com.
About EntasisEntasis Therapeutics
is developing a portfolio of innovative product candidates to treat
serious Gram-negative multi-drug resistant bacterial infections.
Entasis’ anti-infective discovery platform has produced a pipeline
of meaningfully differentiated programs which target serious
bacterial infections, including ETX2514SUL (targeting Acinetobacter
baumannii infections), zoliflodacin (targeting Neisseria
gonorrhoeae), ETX0282CPDP (targeting Enterobacteriaceae
infections), and non-β-lactam PBP inhibitors or NBPs (targeting
Gram-negative infections). www.entasistx.com
Company
Contact
Kyle Dow Entasis Therapeutics (781)
810-0114 kyle.dow@entasistx.com
Investor ContactChris
BrinzeyWestwicke Partners(339)
970-2843Chris.brinzey@westwicke.com
Media ContactKari Watson or
Stefanie TuckMacDougall Biomedical Communications(781)
235-3060kwatson@macbiocom.com or stuck@macbiocom.com
Entasis Therapeutics (NASDAQ:ETTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Entasis Therapeutics (NASDAQ:ETTX)
Historical Stock Chart
From Sep 2023 to Sep 2024